Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ipatasertib - Genentech

Drug Profile

Ipatasertib - Genentech

Alternative Names: GCD 0068; GDC-0068; RG-7440; RO 5532961

Latest Information Update: 01 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Big Ten Cancer Research Consortium; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Genentech; Roche; Roche Farma; SOLTI Breast Cancer Research Group
  • Class Amines; Antineoplastics; Chlorinated hydrocarbons; Heterocyclic bicyclo compounds; Ketones; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; HER2 negative breast cancer; Prostate cancer; Triple negative breast cancer
  • Phase II Gastrointestinal cancer; Ovarian cancer; Solid tumours
  • Phase I/II Endometrial cancer
  • Phase I HER2 positive breast cancer

Most Recent Events

  • 26 Oct 2022 Efficacy and adverse events data from a phase II trial in Solid tumours presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
  • 21 Sep 2022 Hoffmann-La Roche completes a phase Ib trial for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in Italy, France, Switzerland and Spain (PO) (NCT04404140)
  • 14 Sep 2022 National Cancer Institute plans a phase I/II trial for Endometrial cancer (Recurrent, Metastatic disease, Second-line therapy or greater, Combination therapy) (PO) in January 2023 (NCT05538897)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top